Maynard Ryan D
- SEC CIK
- 0001363984
No open-market purchases or sales filed in the past year.
Current role at each company
- IOVA Iovance Biotherapeutics, Inc.Directoras of Jun 18, 2026
- FHTX Foghorn Therapeutics Inc.Chief Financial Officeras of Feb 24, 2026
- TVRD Tvardi Therapeutics, Inc.CHIEF FINANCIAL OFFICERas of Feb 12, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Maynard Ryan D as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
IOVA Iovance Biotherapeutics, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 14, 2024 (view filing) | Nov 12 | 2 days | Maynard Ryan DDirector | SSale | −50.0K | $10.06 | −$503.0K | −87.0%7.50K after | |
| Jun 2, 2022 (view filing) | May 31 | 2 days | Maynard Ryan DDirector | PPurchase | +7.50K | $6.75 | +$50.6K | New position7.50K after |
TVRD Tvardi Therapeutics, Inc.
CHIEF FINANCIAL OFFICER1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2024 (view filing) | Feb 8, 2023 | 369 daysLate | Maynard Ryan DCHIEF FINANCIAL OFFICER | SSale | −5.49K | $0.53 | −$2.91K | −40.7%8.01K after | 10b5-1 |